Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $21.57.

Several brokerages recently issued reports on ZVRA. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Cantor Fitzgerald assumed coverage on shares of Zevra Therapeutics in a research report on Wednesday, January 8th. They set an “overweight” rating and a $25.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Guggenheim assumed coverage on Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target on the stock.

Zevra Therapeutics Stock Down 0.7 %

Zevra Therapeutics stock opened at $8.04 on Tuesday. The firm has a 50 day moving average price of $8.63 and a two-hundred day moving average price of $7.88. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market cap of $429.18 million, a price-to-earnings ratio of -4.08 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the company posted ($0.40) EPS. Equities analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC grew its stake in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after acquiring an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $92,000. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.